Chemotoxicity Prediction Models

tibbi onkoloji ozel 13-4 kapak

Zeynep Gülsüm GÜÇ a, Aziz KARAOĞLU b

aDokuz Eylül Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji BD, İzmir, TÜRKİYE
bDokuz Eylül Üniversitesi Onkoloji Enstitüsü Klinik Onkoloji ABD, İzmir, TÜRKİYE

ABSTRACT
Although there have been many new developments in the systemic treament of cancer such as thyrosin kinase inhibitors and immunoterapy in the recent years, chemotherapy is still the main treatment modality. However aging related processes may reduce to chemotherapy tolerance and increasechemotoxicity in elderly patients. Aging is a heterogeneous process and personalization of cancer treatment is necessary in geriatric patients. In the general population, Performace Status (PS) has been used to estimate tolerance to chemotherapy, but in the elderly population it is not useful. In this review, chemotoxicity prediction models that will help in making daily chemotherapy decision and predict tolerance to chemotherapy will be scrutinized.
Keywords: Cancer; elderly; chemotoxicity

Referanslar

  1. Yancik R, Ries LA. Aging and cancer in America. Hematol Oncol Clin North Am.2000;14: 17-23. [Crossref]  [PubMed]
  2. Feliu J, Heredia-Soto V, Gironés R, JiménezMunarriz B, Saldaña J, Guillén-Ponce C, et al. Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients. Clin Transl Oncol. 2019;12094-19- 02167.
  3. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. Journal of clinical oncology. 2004; 22(22):4626-31. [Crossref]  [PubMed]
  4. Carreca I, Balducci L, Extreman M. Cancer in the older person. Cancer Treatment Reviews. 2005;31:380-402. [Crossref]  [PubMed]
  5. Lichtman SM. Therapy insight: therapeutic challenges in the treatment of elderly patients. Nature Clinical Practice..2006;3: 86-93. [Crossref]  [PubMed]
  6. McKenna, RJ SR. Clinical aspects of cancer in the elderly. Treatment decisions, treatment choices, and follow-up. Cancer. 1994;74(7 Suppl):2107-17. [Crossref]  [PubMed]
  7. Schmucker DL. Age-related changes in liver structure and function: Implications for disease? Experimental gerontology. 2005;40: 650-9. [Crossref]  [PubMed]
  8. Feliu J, Heredia-Soto V, Gironés R, JiménezMunarriz B, Saldaña J, Guillén-Ponce C, et al. Can we avoid the toxicity of chemotherapy in elderly cancer patients? Crit Rev Oncol Hematol. 2018;131: 16-23. [Crossref]  [PubMed]
  9. Marx GM, Blake GM, Galani E, et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol. 2004;15:291-5. [Crossref]  [PubMed]
  10. Peterson LL, Hurria A, Feng T, Mohile SG, Owusu C, Klepin HD, et al. Association between renal function and chemotherapy-related toxicity in older adults with cancer. J. Geriatr. Oncol.2017;8,96-101. [Crossref]  [PubMed]  [PMC]
  11. Begg CB, Carbone PP. Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer. 1983;1;52(11):1986-92. [Crossref]  [PubMed]
  12. Schrijvers D, Highley M, De Bruyn E, Van Oosterom AT, Vermorken JB. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs. 1999;10: 147-53. [Crossref]  [PubMed]
  13. Popa MA, Wallace KJ, Brunello A, Extermann M, Balducci L. Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy. J Geriatr Oncol. 2014;5(3):307-14. [Crossref]  [PubMed]  [PMC]
  14. Rose JH, O'Toole EE, Dawson NV, Lawrence R, Gurley D, Thomas C, et al. Perspectives, preferences, care practices, and outcomes among older and middle-aged patients with late-stage cancer. J Clin Oncol. 2004;22(24):4907-17. [Crossref]  [PubMed]
  15. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin H, Gross CP, et al. Predicting chemotherapy toxicity in older adults withcancer: a prospective multicenter study. J. Clin. Oncol. 2011;29: 3457-65 [Crossref]  [PubMed]  [PMC]
  16. Terret C, Albrand G, Moncenix G, Droz P. Karnofsky performance scale (KPS) or physical performance test (PPT)? That is the question.Crit. Rev. Oncol.Hematol. 2011 77, 142-7. [Crossref]  [PubMed]
  17. Solomon D, Brown AS, Brummel-Smith K, Burgess L, D'Agostino RB, Goldschmidt JW, et al. National Institutes of Health Consensus Development Conference Statement: Geriatric assessment methods for clinical decisionmaking. J Am Soc.1988;36(4):342-7 [Crossref]  [PubMed]
  18. Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann,M, et al. International Society of Geriatric Oncology Consensus on geriatric assessment in older patientes with cancer. J. Clin. Oncol. 2014;32, 2595-603. [Crossref]  [PubMed]  [PMC]
  19. Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol; 20181;36(22):2326- 47. [Crossref]  [PubMed]  [PMC]
  20. Von Gruenigen VE, Huang HQ, Beumer JH, Lankes HA, Tew W, Herzog T, et al. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - an NRG Oncology/Gynecologic Oncology Group study. Gynecol. Oncol. 2017; 144, 459-67. [Crossref]  [PubMed]  [PMC]
  21. Maestu I, Muñoz J, Gómez-Aldaraví L, Esquerdo G, Yubero A, Torregrosa MD, et al. Assessment of functional status, symptoms and comorbidity in elderly patients with advanced non-small-cell lung cancer (NSCLC) treated with gemcitabine and vinorelbine. Clin. Transl. Oncol. 2007;9,99-105. [Crossref]  [PubMed]
  22. Aparicio T, JOuve JL, Teillet L, Gargot D, Subtil F, Le Brun-ly V, et al. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal Cancer in elderly patients. J. Clin. Oncol. 2013;31, 1464-70. [Crossref]  [PubMed]
  23. Lee L, Cheung WY, Atkinson E, Krzyzanowska MK. Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review. J. Clin. Oncol. 2011;29:106-17. [Crossref]  [PubMed]
  24. Korc-Grodzicki B, Holmes HM, Shahrokni A. Geriatric assessment for oncologists: review. Cancer Biol. Med. 2015;12, 261-74.
  25. Buskermolen S, Langius JA, Kruizenga HM, Ligthart-Melis GC, Heymans MW, Verheul HM. Weight loss of 5% or more predicts loss of fat-free mass during palliative chemotherapy in patients with advanced cancer: a pilot study. Nutr. Cancer, 2012;64, 826-32. [Crossref]  [PubMed]
  26. Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br. J. Cance., 2004;90,1905-11. [Crossref]  [PubMed]  [PMC]
  27. Pilnik NG, Ibero MM, Carri D, Mareca O. Influence of some clinical parameters in the tolerance to treatment in elderly patients with advancer lung cancer. J. Clin. Oncol.2010;28 (suppl), e19600. [Crossref]
  28. Goodwin,J.S, Zhang DD, Ostir GV. Effect of depression on diagnosis, treatment,and survival of older women with breast cancer. J. Am. Geriatr. Soc.2004;52,106-11. [Crossref]  [PubMed]  [PMC]
  29. Extermann M, Boler I, Reich RR, Lyman GH, Brown, DeFelice J, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377-86. [Crossref]  [PubMed]
  30. Extermann M, Bonetti M, Sledge GW, O'Dwyer PJ, Bonomi P, Benson AB. MAX2-a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials. Eur J Cancer. 2004;40: 1193-8. [Crossref]  [PubMed]
  31. Extermann M, Chen H, Cantor AB, et al. Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study. Eur J Cancer. 2002;38:1466-73. [Crossref]  [PubMed]
  32. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP,et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457-65. [Crossref]  [PubMed]  [PMC]
  33. Hurria A, Mohile S, Gajra A, Klepin H, Muss H, Chapman A, et al. Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer. J Clin Oncol. 2016;34(20):2366-71. [Crossref]  [PubMed]  [PMC]
  34. O'Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin. Cancer Res. 2009;15:4806-44. [Crossref]  [PubMed]  [PMC]
  35. Kim JW, Lee YG, Hwang IG, Song HS, Koh SJ, Ko YH, et al. Predicting cumulative incidence of adverse events in older patients with cancer undergoing firstline palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study. Br. J. Cancer. 2018;118:1169-75. [Crossref]  [PubMed]  [PMC]